J
Jan Mester
Researcher at French Institute of Health and Medical Research
Publications - 76
Citations - 3956
Jan Mester is an academic researcher from French Institute of Health and Medical Research. The author has contributed to research in topics: Receptor & Oviduct. The author has an hindex of 34, co-authored 75 publications receiving 3861 citations. Previous affiliations of Jan Mester include University of Tampere.
Papers
More filters
Journal ArticleDOI
Common non-hormone binding component in non-transformed chick oviduct receptors of four steroid hormones.
Irene Joab,Christine Radanyi,Michel Renoir,Thierry Buchou,Maria-Grazia Catelli,Nadine Binart,Jan Mester,Etienne-Emile Baulieu +7 more
TL;DR: The results suggest that the antigenic determinant recognized by BF4 is present on a non-hormone binding unit, which is identified as a polypeptide of molecular weight (MW) 90,000 in the case of the progesterone receptor, and that this unit is common to other 8S non-transformed chicken steroid receptors.
Journal ArticleDOI
Estrogen induction of the cyclin D1 promoter: involvement of a cAMP response-like element.
TL;DR: A mechanism in which ATF-2/c-Jun heterodimers bind to the CRE-D1 element and mediate the activation of cyclin D1 promoter by the ER is proposed, which represents a pathway by which estrogens control the proliferation of target cells.
Journal ArticleDOI
Antitumor activity of oxaliplatin in combination with 5-fluorouracil and the thymidylate synthase inhibitor AG337 in human colon, breast and ovarian cancers
Eric Raymond,Christine Buquet-Fagot,Siham Djelloul,Jan Mester,Esteban Cvitkovic,P Allain,Christophe Louvet,Christian Gespach +7 more
TL;DR: In vivo and in vitro, synergistic antiproliferative effects were observed when oxaliplatin was added to 5-FU and AG337, and synergistic effects of combinations were maintained in colon HT29-5-FU cancer cells.
Journal ArticleDOI
Tamoxifen is a potent "pure" anti-oestrogen in chick oviduct.
TL;DR: Results are presented which illustrate that the theory of anti-oestrogenic action does not hold for tamoxifen (ICI 46,474) in the chicken oviduct.
Journal Article
The c-kit Tyrosine Kinase Inhibitor STI571 for Colorectal Cancer Therapy
Samir Attoub,Christine Rivat,Sylvie Rodrigues,Saskia Van Bocxlaer,Monique Bedin,Erik Bruyneel,Christophe Louvet,Michel Kornprobst,Thierry André,Marcus Mareel,Jan Mester,Christian Gespach +11 more
TL;DR: Encouraging results warrant further preclinical investigations and clinical trials on the use of the c-kit inhibitor STI571 as a chemotherapeutic agent in colon cancer prevention and in treatment of advanced colorectal cancers associated with liver metastases.